# 510(k) SUMMARY

as required per 807.92(c)

## Submitters Name, Address:

Siemens Medical Solutuions Electromedical Systems Group, PCS

16 Electronics Avenue Danvers, MA 01923 Tel: (978) 907-7500

Fax: (978) 750-6879

Official Correspondent: Connie Hertel, Director

Quality Assurance & Regulatory Affairs

Contact person for this submission: Penelope H. Greco Date submission was prepared: June 20, 2003

## Trade Name, Common Name and Classification Name:

#### A. Trade Name:

**INFINITY MegaCare** 

# B. Common Name, Classification Name, Class and Regulation Number:

Common Name	Product Code	Class	Regulation Number
System, ECG Analysis	LOS		
Computer, diagnostic, programmable	DOK	II	21CFR 870.1425

## Predicate Device Identification:

K980625	Infinity MultiView WorkStation Enhanced with
	Diagnostic Statements (Rest ECG)
K992637	Muse Cardiovascular Information System
K974420	TraceMaster ECG Management System
K946281	Burdick Eclipse 4 Electrocardiograph

#### Device Description:

INFINITY MegaCare is a computer software program that allows viewing, manual editing, printing and archiving of digitized electrocardiograph records from Rest ECG devices, Exercise ECG devices, ambulance ECG devices, Holter ECG devices and the INFINITY Monitoring System.

#### Page 1 of 2

## **COMPANY CONFIDENTIAL**

## **Siemens Medical Solutuions**

Electromedical Systems Group, PCS

16 Electronics Avenue Danvers, MA 01923

Tel: (978) 907-7500 Fax: (978) 750-6879 INFINITY MegaCare uses the Microsoft Windows 2000 server operating system, Microsoft IIS Web server, and Microsoft SQL Server 2000 relational database. The system consists of a software application, which is installed on a user provided IBM compatible server running the Microsoft Windows 2000 Server operation system. MegaCare utilizes the ECG analysis algorithm developed under the direction of Dr. Peter MacFarlane at the University of Glasgow and used for the Infinity MVWS Rest ECG (K980625) and Burdick's Eclipse 4 Electrocardiograph (K946281).

#### Intended Use:

INFINITY MegaCare is a software application for viewing, manual editing, printing, and archiving of digitized electrocardiograph records from Rest ECG devices, Exercise ECG devices, Ambulance ECG devices, Holter ECG devices and the Infinity Monitoring System.

INFINITY MegaCare is intended to provide analysis or reanalysis of Rest ECG's and to provide preliminary data for editing and confirmation by a physician. Infinity MegaCare can provide a serial comparison of Rest ECG data to facilitate the review of current and previous Rest ECG's.

INFINITY MegaCare is designed for network compatibility to facilitate retrieval of data and to interface with other hospital information systems though HL7 protocols.

Assessment of non-clinical performance data for equivalence:

Substantially equivalent (Section S)

Assessment of clinical performance data for equivalence:

Substantially equivalent (Section T)

Biocompatability:

Not applicable

Sterilization:

Not applicable

Standards and Guidance: Section R

Page 2 of 2

#### COMPANY CONFIDENTIAL

16 Electronics Avenue Danvers, MA 01923

Tel: (978) 907-7500 Fax: (978) 750-6879



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

SEP - 9 2003

Siemens Medical Solutions USA, Inc. Electromedical Systems Group, PCS c/o Ms. Penelope H. Greco Regulatory Submissions Manager 16 Electronics Avenue Danvers, MA 01923

Re: K031970

Trade Name: Siemens INFINITY MegaCare

Regulation Number: 21 CFR 870.1425

Regulation Name: Programmable diagnostic computer

Regulatory Class: Class II (two)

Product Code: DQK Dated: June 20, 2003 Received: June 26, 2003

#### Dear Ms. Greco:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

# Page 2 – Ms. Penelope H. Greco

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

-Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

**Enclosure** 

	Page_1_of_1
510(k) Number (if known):	
Device Name: Siemens INFINITY	MegaCare
Indications for Use:	
archiving of digitized electrocardiog	plication for viewing, manual editing, printing, and graph records from Rest ECG devices, Exercise ECG Holter ECG devices and the Infinity Monitoring
provide preliminary data for editing	rovide analysis or reanalysis of Rest ECG's and to and confirmation by a physician. INFINITY parison of Rest ECG data to facilitate the review of
Ç	network compatibility to facilitate retrieval of data information systems though HL7 protocols.
Healthcare Professionals, i.e. physic	environment where patient care is provided by cians, nurses, and technicians, trained on the use of the e of the device is indicated, based upon their nt's medical condition.
The device is intended for use with	all patient populations.
MRI Compatibility Statement: The INFINITY MegaCare is not compatible	for use in a MRI magnetic field.
(PLEASE DO NOT WRITE BELOW NEEDED)	THIS LINE-CONTINUE ON ANOTHER PAGE IF
Concurrence of CD	RH, Office of Device Evaluation (ODE)
Prescription Use X (Per 21 CFR 801.109)	OR Over-The-Counter Use
	vision Sign-Off) ision of Cardiovascular Devices
510	(k) Number <u>K031970</u>